HAOHAIBIOTEC：2024THIRDQUARTERLYREPORT;AMENDMENTSTOTHEWORKINGRULESOFTHESTRATEGYCOMMITTEEANDTHEAUDITCOMMITTEE;ANDCHANGEOFNAMEOFTHESTRATEGYCOMMITTEE.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.Shanghai Haohai Biological Technology Co.,Ltd.*上海昊海生物科技股份有限公司(a joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:6826)2024 THIRD QUARTERLY REPORT;AMENDMENTS TO THE WORKING RULES OF

3、 THE STRATEGY COMMITTEE AND THE AUDIT COMMITTEE;ANDCHANGE OF NAME OF THE STRATEGY COMMITTEE2024 THIRD QUARTERLY REPORTThis part of announcement is made by Shanghai Haohai Biological Technology Co.,Ltd.*(the“Company”,together with its subsidiaries,the“Group”)pursuant to Rules 13.09(2)and 13.10B of th

4、e Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Part XIVA of The Securities and Futures Ordinance(Cap.571 of the Laws of Hong Kong)to provide shareholders of the Company and the public with the updated financial information of the Company.Set out herein

5、 are the unaudited results(the“Third Quarterly Report”)of the Group for the three months and nine months ended 30 September 2024,which were simultaneously published on the website of the Shanghai Stock Exchange by the Company.The financial information contained in the Third Quarterly Report has been

6、 prepared in accordance with the Chinese Accounting Standards for Business Enterprises,and contains accounting data which has not been audited.The Third Quarterly Report set out below is written in both Chinese and English.In the case of any discrepancies,the Chinese version of the Third Quarterly R